Friday 6 November 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.

Revenue: +1.33%
EPS: +418.2%
Free cash flow: −6.83%
Total debt: −42.2%

Quarter to June 2026, against a year earlier

72.79 0.13 +0.18%

Follow TECH

Alert me

Market cap: $11.4B
P/E: 62.2×
Fwd P/E: 54.2×
Dividend yield: 0.44%
F-score: 9/9
Altman Z: 15.50
Beneish M: −2.52
Dividend safety: 78/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bio-Techne Corp (TECH) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Bio-Techne Corp (TECH) trades at a price to free cash flow of 43.1×. Over the past ten years it has ranged from 16.9× (January 2016) to 79.3× (February 2021); the current reading is higher than 48% of that period. That is above the Biotechnology industry median of 24.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/TECH/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Bio-Techne Corp price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/TECH/metrics/price-to-free-cash-flow">Bio-Techne Corp (TECH) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2026	41.9×	32.51%
FY2025	31.6×	(33.96%)
FY2024	47.8×	(19.42%)
FY2023	59.4×	22.42%
FY2022	48.5×	(14.44%)
FY2021	56.7×	(13.79%)
FY2020	65.7×	29.86%
FY2019	50.6×	36.15%
FY2018	37.2×	8.98%
FY2017	34.1×	3.51%

Period	Price to free cash flow	Change
Jun 2026	41.9×	38.14%
Mar 2026	30.3×	(26.26%)
Dec 2025	41.1×	6.46%
Sep 2025	38.6×	22.19%
42 more quarters	Free account

Against its own ten years

Low 16.9× High 79.3×

Ten-year median 44.2×

Current reading's percentile 48

Company	Price to free cash flow
TWST Twist Bioscience Corporation compare	n/m
IBRX ImmunityBio, Inc. compare	n/m
KYMR Kymera Therapeutics, Inc. compare	n/m
SMMT Summit Therapeutics PLC compare	n/m
PCVX Vaxcyte, Inc. compare	n/m
BMRN BioMarin Pharmaceutical Inc. compare	20.0×
TECH Bio-Techne Corp	43.1×
CAI Caris Life Sciences,�Inc. compare	191×
TGTX TG Therapeutics, Inc. compare	474×
Biotechnology industry median	24.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Bio-Techne Corp (TECH) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on TECH

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on TECH

Stockrow Weekly